GlassScriptPhysician profile
Amanda M Salay
NPI 1982356911
$2,826.99
in general payments reported to CMS, 2019-2025
20 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $926 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.24 | 2024-2025 | |
| Argenx US, INC. | $322.76 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Scilex Pharmaceuticals INC. | $321.97 | 2024-2025 | |
| Lundbeck LLC | $246.95 | 2024-2025 | Vyepti |
| Harmony Biosciences LLC | $223.82 | 2024-2025 | |
| Ucb, INC. | $211.07 | 2024-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $147.17 | 2024-2025 | Emgality, Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $109.77 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $100.63 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Neurocrine Biosciences, INC. | $93.47 | 2024-2025 | Ingrezza |
| Pfizer INC. | $79.71 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $68.10 | 2024-2025 | Horizant |
| Supernus Pharmaceuticals, INC. | $34.82 | 2025 | Qelbree |
| Kyowa Kirin, INC. | $28.81 | 2024 | Nourianz |
| Jazz Pharmaceuticals INC. | $25.31 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24.20 | 2024 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $23.23 | 2025 | Ultomiris |
| Valinor Pharma, LLC | $21.93 | 2025 | Movantik |
| Tonix Medicines, INC. | $21.31 | 2025 | Zembrace Symtouch |
| Idorsia Pharmaceuticals US INC | $16.72 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Salay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.